March 29, 2019 / 12:13 AM / 2 months ago

AstraZeneca and Daiichi Sankyo to jointly develop cancer drug

March 28 (Reuters) - British drugmaker AstraZeneca Plc said late on Thursday it entered into a collaboration deal with Daiichi Sankyo Co Ltd of Japan to develop trastuzumab deruxtecan, a proprietary antibody-drug conjugate for cancer treatment.

Under the terms of the deal, AstraZeneca will pay Daiichi Sankyo up to $6.90 billion in total consideration, including $1.35 billion in upfront payment, Daiichi said in a separate statement. (Reporting by Bhargav Acharya in Bengaluru; Editing by Sandra Maler)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below